Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Feb 12

PMID 33572595

Citations 55

Authors

Stanislaw Supplitt

Pawel Karpinski

Maria Sasiadek

Izabela Laczmanska

Affiliations

Soon will be listed here.

Abstract

Over the last decades, transcriptome profiling emerged as one of the most powerful approaches in oncology, providing prognostic and predictive utility for cancer management. The development of novel technologies, such as revolutionary next-generation sequencing, enables the identification of cancer biomarkers, gene signatures, and their aberrant expression affecting oncogenesis, as well as the discovery of molecular targets for anticancer therapies. Transcriptomics contribute to a change in the holistic understanding of cancer, from histopathological and organic to molecular classifications, opening a more personalized perspective for tumor diagnostics and therapy. The further advancement on transcriptome profiling may allow standardization and cost reduction of its analysis, which will be the next step for transcriptomics to become a canon of contemporary cancer medicine.

Citing Articles

Transcriptomics and microbiome insights reveal the protective mechanism of mulberry-derived postbiotics against inflammation in LPS-induced mice.

Abbas Z, Tong Y, Zhang J, Sammad A, Wang J, Ahmad B Front Immunol. 2025; 16:1536694.

PMID: 40040706 PMC: 11876837. DOI: 10.3389/fimmu.2025.1536694.

Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models.

Jin Y, Chen P, Zhou H, Mu G, Wu S, Zha Z Front Immunol. 2025; 16:1505868.

PMID: 39995668 PMC: 11847686. DOI: 10.3389/fimmu.2025.1505868.

Volatile Organic Metabolites as Potential Biomarkers for Genitourinary Cancers: Review of the Applications and Detection Methods.

Holbrook K, Lee W Metabolites. 2025; 15(1).

PMID: 39852380 PMC: 11767221. DOI: 10.3390/metabo15010037.

Advances in DNA/RNA Sequencing and Their Applications in Acute Myeloid Leukemia (AML).

Ahmed F, Zhong J Int J Mol Sci. 2025; 26(1.

PMID: 39795930 PMC: 11720148. DOI: 10.3390/ijms26010071.

Systematic identification of pathological mechanisms, prognostic biomarkers and therapeutic targets by integrating lncRNA expression variation in salivary gland mucoepidermoid carcinoma.

Zou Y, Shan X, Qiu J, Geng Y, Xie S, Xiang R Sci Rep. 2025; 15(1):1573.

PMID: 39794354 PMC: 11724123. DOI: 10.1038/s41598-025-85535-9.

References

Johann Jr D, Steliga M, Shin I, Yoon D, Arnaoutakis K, Hutchins L . Liquid biopsy and its role in an advanced clinical trial for lung cancer. Exp Biol Med (Maywood). 2018; 243(3):262-271. PMC: 5813874. DOI: 10.1177/1535370217750087. View

Fan J, Lee H, Lee S, Ryu D, Lee S, Xue C . Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. Genome Res. 2018; 28(8):1217-1227. PMC: 6071640. DOI: 10.1101/gr.228080.117. View

Rodgers L, O hAinmhire E, Young A, Burdette J . Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium. Oncotarget. 2016; 7(22):32785-95. PMC: 5078051. DOI: 10.18632/oncotarget.9051. View

Goldsworthy S, Goldsworthy T, Sprankle C, Butterworth B . Variation in expression of genes used for normalization of Northern blots after induction of cell proliferation. Cell Prolif. 1993; 26(6):511-8. DOI: 10.1111/j.1365-2184.1993.tb00029.x. View

Cieslik M, Chinnaiyan A . Cancer transcriptome profiling at the juncture of clinical translation. Nat Rev Genet. 2017; 19(2):93-109. DOI: 10.1038/nrg.2017.96. View

Byron S, Van Keuren-Jensen K, Engelthaler D, Carpten J, Craig D . Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet. 2016; 17(5):257-71. PMC: 7097555. DOI: 10.1038/nrg.2016.10. View

Jin Z, Liu Y . DNA methylation in human diseases. Genes Dis. 2018; 5(1):1-8. PMC: 6147084. DOI: 10.1016/j.gendis.2018.01.002. View

Heather J, Chain B . The sequence of sequencers: The history of sequencing DNA. Genomics. 2015; 107(1):1-8. PMC: 4727787. DOI: 10.1016/j.ygeno.2015.11.003. View

Lennox K, Owczarzy R, Thomas D, Walder J, Behlke M . Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. Mol Ther Nucleic Acids. 2013; 2:e117. PMC: 3759741. DOI: 10.1038/mtna.2013.46. View

10.

Bianchi F, Nicassio F, Marzi M, Belloni E, DallOlio V, Bernard L . A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011; 3(8):495-503. PMC: 3377091. DOI: 10.1002/emmm.201100154. View

11.

Park J, Shim J, Yoon S, Kim S, Chang J, Kang S . Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma. Sci Rep. 2019; 9(1):10555. PMC: 6646357. DOI: 10.1038/s41598-019-47066-y. View

12.

Liu Y, Dou M, Song X, Dong Y, Liu S, Liu H . The emerging role of the piRNA/piwi complex in cancer. Mol Cancer. 2019; 18(1):123. PMC: 6688334. DOI: 10.1186/s12943-019-1052-9. View

13.

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

14.

Gu X, Li B, Jiang M, Fang M, Ji J, Wang A . RNA sequencing reveals differentially expressed genes as potential diagnostic and prognostic indicators of gallbladder carcinoma. Oncotarget. 2015; 6(24):20661-71. PMC: 4653033. DOI: 10.18632/oncotarget.3861. View

15.

Vuong H, Cheng F, Lin C, Zhao Z . Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach. Genome Med. 2014; 6(10):81. PMC: 4213513. DOI: 10.1186/s13073-014-0081-7. View

16.

Cheng Q, Li J, Fan F, Cao H, Dai Z, Wang Z . Identification and Analysis of Glioblastoma Biomarkers Based on Single Cell Sequencing. Front Bioeng Biotechnol. 2020; 8:167. PMC: 7066068. DOI: 10.3389/fbioe.2020.00167. View

17.

Nassri A, Zhu H, Muftah M, Ramzan Z . Epidemiology and Survival of Esophageal Cancer Patients in an American Cohort. Cureus. 2018; 10(4):e2507. PMC: 6007500. DOI: 10.7759/cureus.2507. View

18.

Cao M, Deng X, Su S, Zhang F, Xiao X, Hu Q . Protamine sulfate-nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells. Nanoscale. 2013; 5(24):12120-5. DOI: 10.1039/c3nr04056a. View

19.

Zivicova V, Gal P, Mifkova A, Novak S, Kaltner H, Kolar M . Detection of Distinct Changes in Gene-expression Profiles in Specimens of Tumors and Transition Zones of Tenascin-positive/-negative Head and Neck Squamous Cell Carcinoma. Anticancer Res. 2018; 38(3):1279-1290. DOI: 10.21873/anticanres.12350. View

20.

Xie C, Tammi M . CNV-seq, a new method to detect copy number variation using high-throughput sequencing. BMC Bioinformatics. 2009; 10:80. PMC: 2667514. DOI: 10.1186/1471-2105-10-80. View